Please login to the form below

Not currently logged in
Email:
Password:

Elocta

This page shows the latest Elocta news and features for those working in and with pharma, biotech and healthcare.

Shire claims EU approval for haemophilia A drug Adynovi

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share. ... It is jostling for market share with other long-acting Factor VIII products for haemophilia A, including Bayer’s Kovaltry and Sobi's Elocta and while Shire

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    The process is never guaranteed, but we are hoping Elocta will be accessible to patients from 1 July,” he says. ... Compared to normal timelines, the requirements for haemophilia could be quite frustrating, but Neil is sanguine about the need to wait,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics